CIA
SCPH

Concurrent Investment Advisors’s scPharmaceuticals SCPH Stock Holding History

Concurrent Investment Advisors’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,510
Closed -$78.4K – 985
2023
Q4 		$78.4K Buy
+12,510
New +$71.6K ﹤0.01% 822

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Concurrent Investment Advisors's SCPH Position: Q1 2024 in Review

Concurrent Investment Advisors sold out of scPharmaceuticals (SCPH) in Q1 2024, closing a stake of 12,510 shares — an estimated $78.4K sold.

Concurrent Investment Advisors first reported a position in SCPH in Q4 2023 and held it in 1 quarter. The position peaked at $78.4K in Q4 2023. 76 funds tracked by Wall St. Rank hold SCPH as of Q1 2024.

  • Concurrent Investment Advisors reported no remaining scPharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Concurrent Investment Advisors sold 12,510 scPharmaceuticals shares in Q1 2024, an estimated $78.4K.
  • Concurrent Investment Advisors first reported a position in scPharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Concurrent Investment Advisors's scPharmaceuticals position peaked at $78.4K in Q4 2023.
  • 76 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2024.

Based on Concurrent Investment Advisors's 13F filing for Q1 2024, filed 7 May 2024.